U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C24H28F3N3O3
Molecular Weight 463.4935
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TAFENOQUINE

SMILES

Cc1cc(nc2c(cc(c(c12)Oc3cccc(c3)C(F)(F)F)OC)NC(C)CCCN)OC

InChI

InChIKey=LBHLFPGPEGDCJG-UHFFFAOYSA-N
InChI=1S/C24H28F3N3O3/c1-14-11-20(32-4)30-22-18(29-15(2)7-6-10-28)13-19(31-3)23(21(14)22)33-17-9-5-8-16(12-17)24(25,26)27/h5,8-9,11-13,15,29H,6-7,10,28H2,1-4H3

HIDE SMILES / InChI

Molecular Formula C24H28F3N3O3
Molecular Weight 463.4935
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Tafenoquine, an 8-aminoquinoline antimalarial, is active against all the stages of Plasmodium species that include the hypnozoite (dormant stage) in the liver. Studies in vitro with the erythrocytic forms of Plasmodium falciparum suggest that tafenoquine may exert its effect by inhibiting hematin polymerization and inducing apoptotic like death of the parasite. In addition to its effect on the parasite, tafenoquine causes red blood cell shrinkage in vitro. Tafenoquine is active against pre-erythrocytic (liver) and erythrocytic (asexual) forms as well as gametocytes of Plasmodium species that include P. falciparum and P. vivax. The activity of tafenoquine against the pre-erythrocytic liver stages of the parasite, prevents the development of the erythrocytic forms of the parasite.

CNS Activity

Curator's Comment:: Drug related radioactivity in the brain indicated minimal penetration of the blood brain barrier.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
ARAKODA

Approved Use

ARAKODA is an antimalarial indicated for the prophylaxis of malaria in patients aged 18 years and older

Launch Date

1533600000000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
147 ng/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TAFENOQUINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: HIGH-FAT
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
70 μg × h/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TAFENOQUINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: HIGH-FAT
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
16.5 day
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TAFENOQUINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: HIGH-FAT
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
0.5%
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TAFENOQUINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: HIGH-FAT
Doses

Doses

DosePopulationAdverse events​
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Other AEs: Headache, Sinus headache...
Other AEs:
Headache (15%)
Sinus headache (15%)
Migraine (15%)
Tension headache (15%)
Dizziness (1%)
Dizziness postural (1%)
Nervous system disorders (22%)
Musculoskeletal and connective tissue disorders (29%)
Back pain (14%)
Gastrointestinal disorders (36%)
Diarrhea (18%)
Nausea (7%)
Vomiting (5%)
Psychiatric disorders (5%)
Abnormal dreams (2%)
Insomnia (2%)
Nightmares (2%)
Sleep disorder (2%)
Somnambulism (2%)
Anxiety disorder (1%)
Panic attack (1%)
Ear and labyrinth disorders (7%)
Motion sickness (5%)
Vertigo (5%)
Vertigo positional (5%)
Stress (1%)
Headache (15%)
Sinus headache (15%)
Migraine (15%)
Tension headache (15%)
Dizziness (1%)
Dizziness postural (1%)
Nervous system disorders (22%)
Musculoskeletal and connective tissue disorders (29%)
Back pain (14%)
Gastrointestinal disorders (36%)
Diarrhea (18%)
Nausea (7%)
Vomiting (5%)
Psychiatric disorders (5%)
Abnormal dreams (2%)
Insomnia (2%)
Nightmares (2%)
Sleep disorder (2%)
Somnambulism (2%)
Anxiety disorder (1%)
Panic attack (1%)
Ear and labyrinth disorders (7%)
Motion sickness (5%)
Vertigo (5%)
Vertigo positional (5%)
Stress (1%)
Sources:
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Other AEs: Headache, Sinus headache...
Other AEs:
Headache (32%)
Sinus headache (32%)
Migraine (32%)
Tension headache (32%)
Dizziness (5%)
Dizziness postural (5%)
Nervous system disorders (35%)
Musculoskeletal and connective tissue disorders (27%)
Back pain (14%)
Gastrointestinal disorders (31%)
Diarrhea (5%)
Nausea (5%)
Vomiting (2%)
ALT increased (4%)
Psychiatric disorders (2%)
Abnormal dreams (1%)
Insomnia (1%)
Nightmares (1%)
Sleep disorder (1%)
Somnambulism (1%)
Depression (1%)
Depressed mood (1%)
Hemolytic anemia (<1%)
Anemia (<1%)
Thrombocytopenia (<1%)
Hyperacusis (<1%)
Meniere's disease (<1%)
Hyperbilirubinemia (<1%)
Jaundice cholestatic (<1%)
Blood bilirubin increased (<1%)
Blood creatinine increased (<1%)
Glomerular filtration rate decreased (<1%)
Amnesia (<1%)
Coordination abnormal (<1%)
Hyperesthesia (<1%)
Hypoesthesia (<1%)
Somnolence (<1%)
Visual field defect (<1%)
Urticaria (<1%)
Headache (32%)
Sinus headache (32%)
Migraine (32%)
Tension headache (32%)
Dizziness (5%)
Dizziness postural (5%)
Nervous system disorders (35%)
Musculoskeletal and connective tissue disorders (27%)
Back pain (14%)
Gastrointestinal disorders (31%)
Diarrhea (5%)
Nausea (5%)
Vomiting (2%)
ALT increased (4%)
Psychiatric disorders (2%)
Abnormal dreams (1%)
Insomnia (1%)
Nightmares (1%)
Sleep disorder (1%)
Somnambulism (1%)
Depression (1%)
Depressed mood (1%)
Hemolytic anemia (<1%)
Anemia (<1%)
Thrombocytopenia (<1%)
Hyperacusis (<1%)
Meniere's disease (<1%)
Hyperbilirubinemia (<1%)
Jaundice cholestatic (<1%)
Blood bilirubin increased (<1%)
Blood creatinine increased (<1%)
Glomerular filtration rate decreased (<1%)
Amnesia (<1%)
Coordination abnormal (<1%)
Hyperesthesia (<1%)
Hypoesthesia (<1%)
Somnolence (<1%)
Visual field defect (<1%)
Urticaria (<1%)
Sources:
400 mg 1 times / day multiple, oral
Studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 34 years (range: 18-50 years)
Health Status: unhealthy
Age Group: 34 years (range: 18-50 years)
Sex: M+F
Sources:
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
Health Status: unhealthy
Age Group: adolescents; adults
Sex: M+F
Sources:
Disc. AE: ALT increased, Hemoglobin decreased...
Other AEs: ALT increased, Hemoglobin decreased...
AEs leading to
discontinuation/dose reduction:
ALT increased (0.7%)
Hemoglobin decreased (0.4%)
GFR decreased (0.2%)
Malaria (0.5%)
Pneumonia (0.1%)
Viral infection (0.1%)
Fall (0.1%)
Joint injury (0.1%)
Meniscus lesion (0.1%)
Thermal burn (0.1%)
Soft tissue injury (0.1%)
Upper limb fracture (0.1%)
Upper abdominal pain (0.1%)
Irritable bowel syndrome (0.1%)
Musculoskeletal pain (0.1%)
Depression (0.1%)
Metamorphopsia (0.1%)
Night blindness (0.1%)
Rash (0.1%)
Lactose intolerance (0.1%)
Hyperbilirubinemia (0.1%)
Other AEs:
ALT increased (0.7%)
Hemoglobin decreased (0.4%)
GFR decreased (0.2%)
Malaria (0.5%)
Pneumonia (0.1%)
Viral infection (0.1%)
Fall (0.1%)
Joint injury (0.1%)
Meniscus lesion (0.1%)
Thermal burn (0.1%)
Soft tissue injury (0.1%)
Upper limb fracture (0.1%)
Upper abdominal pain (0.1%)
Irritable bowel syndrome (0.1%)
Musculoskeletal pain (0.1%)
Depression (0.1%)
Metamorphopsia (0.1%)
Night blindness (0.1%)
Rash (0.1%)
Lactose intolerance (0.1%)
Hyperbilirubinemia (0.1%)
Sources:
600 mg 1 times / day multiple, oral
Highest studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
healthy
600 mg 1 times / week multiple, oral
Highest studied dose
Dose: 600 mg, 1 times / week
Route: oral
Route: multiple
Dose: 600 mg, 1 times / week
Sources:
healthy
600 mg single, oral
Highest studied dose
healthy
400 mg 1 times / day multiple, oral
Studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources:
healthy
Disc. AE: Nausea, Vomiting...
AEs leading to
discontinuation/dose reduction:
Nausea (1 patient)
Vomiting (1 patient)
Sources:
600 mg single, oral
Studied dose
healthy
Other AEs: CPK increased, Hemoglobin increased...
Other AEs:
CPK increased (4%)
Hemoglobin increased (2%)
Hypersensitivity (2%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Anxiety disorder 1%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Anxiety disorder 1%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Dizziness postural 1%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Dizziness postural 1%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Dizziness 1%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Dizziness 1%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Panic attack 1%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Panic attack 1%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Stress 1%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Stress 1%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Back pain 14%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Back pain 14%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Headache 15%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Headache 15%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Migraine 15%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Migraine 15%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Sinus headache 15%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Sinus headache 15%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Tension headache 15%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Tension headache 15%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Diarrhea 18%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Diarrhea 18%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Abnormal dreams 2%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Abnormal dreams 2%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Insomnia 2%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Insomnia 2%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Nightmares 2%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Nightmares 2%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Sleep disorder 2%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Sleep disorder 2%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Somnambulism 2%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Somnambulism 2%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Nervous system disorders 22%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Nervous system disorders 22%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Musculoskeletal and connective tissue disorders 29%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Musculoskeletal and connective tissue disorders 29%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Gastrointestinal disorders 36%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Gastrointestinal disorders 36%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Motion sickness 5%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Motion sickness 5%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Psychiatric disorders 5%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Psychiatric disorders 5%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Vertigo positional 5%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Vertigo positional 5%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Vertigo 5%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Vertigo 5%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Vomiting 5%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Vomiting 5%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Ear and labyrinth disorders 7%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Ear and labyrinth disorders 7%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Nausea 7%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Nausea 7%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
healthy, 29 years (range: 17-69 years)
Health Status: healthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Abnormal dreams 1%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Abnormal dreams 1%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Depressed mood 1%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Depressed mood 1%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Depression 1%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Depression 1%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Insomnia 1%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Insomnia 1%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Nightmares 1%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Nightmares 1%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Sleep disorder 1%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Sleep disorder 1%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Somnambulism 1%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Somnambulism 1%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Back pain 14%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Back pain 14%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Psychiatric disorders 2%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Psychiatric disorders 2%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Vomiting 2%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Vomiting 2%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Musculoskeletal and connective tissue disorders 27%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Musculoskeletal and connective tissue disorders 27%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Gastrointestinal disorders 31%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Gastrointestinal disorders 31%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Headache 32%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Headache 32%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Migraine 32%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Migraine 32%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Sinus headache 32%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Sinus headache 32%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Tension headache 32%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Tension headache 32%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Nervous system disorders 35%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Nervous system disorders 35%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
ALT increased 4%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
ALT increased 4%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Diarrhea 5%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Diarrhea 5%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Dizziness postural 5%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Dizziness postural 5%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Dizziness 5%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Dizziness 5%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Nausea 5%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Nausea 5%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Amnesia <1%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Amnesia <1%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Anemia <1%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Anemia <1%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Blood bilirubin increased <1%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Blood bilirubin increased <1%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Blood creatinine increased <1%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Blood creatinine increased <1%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Coordination abnormal <1%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Coordination abnormal <1%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Glomerular filtration rate decreased <1%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Glomerular filtration rate decreased <1%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Hemolytic anemia <1%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Hemolytic anemia <1%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Hyperacusis <1%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Hyperacusis <1%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Hyperbilirubinemia <1%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Hyperbilirubinemia <1%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Hyperesthesia <1%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Hyperesthesia <1%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Hypoesthesia <1%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Hypoesthesia <1%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Jaundice cholestatic <1%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Jaundice cholestatic <1%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Meniere's disease <1%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Meniere's disease <1%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Somnolence <1%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Somnolence <1%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Thrombocytopenia <1%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Thrombocytopenia <1%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Urticaria <1%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Urticaria <1%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Visual field defect <1%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Visual field defect <1%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 29 years (range: 17-69 years)
Health Status: unhealthy
Age Group: 29 years (range: 17-69 years)
Sex: M+F
Sources:
Depression 0.1%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
Health Status: unhealthy
Age Group: adolescents; adults
Sex: M+F
Sources:
Fall 0.1%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
Health Status: unhealthy
Age Group: adolescents; adults
Sex: M+F
Sources:
Hyperbilirubinemia 0.1%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
Health Status: unhealthy
Age Group: adolescents; adults
Sex: M+F
Sources:
Irritable bowel syndrome 0.1%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
Health Status: unhealthy
Age Group: adolescents; adults
Sex: M+F
Sources:
Joint injury 0.1%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
Health Status: unhealthy
Age Group: adolescents; adults
Sex: M+F
Sources:
Lactose intolerance 0.1%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
Health Status: unhealthy
Age Group: adolescents; adults
Sex: M+F
Sources:
Meniscus lesion 0.1%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
Health Status: unhealthy
Age Group: adolescents; adults
Sex: M+F
Sources:
Metamorphopsia 0.1%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
Health Status: unhealthy
Age Group: adolescents; adults
Sex: M+F
Sources:
Musculoskeletal pain 0.1%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
Health Status: unhealthy
Age Group: adolescents; adults
Sex: M+F
Sources:
Night blindness 0.1%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
Health Status: unhealthy
Age Group: adolescents; adults
Sex: M+F
Sources:
Pneumonia 0.1%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
Health Status: unhealthy
Age Group: adolescents; adults
Sex: M+F
Sources:
Rash 0.1%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
Health Status: unhealthy
Age Group: adolescents; adults
Sex: M+F
Sources:
Soft tissue injury 0.1%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
Health Status: unhealthy
Age Group: adolescents; adults
Sex: M+F
Sources:
Thermal burn 0.1%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
Health Status: unhealthy
Age Group: adolescents; adults
Sex: M+F
Sources:
Upper abdominal pain 0.1%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
Health Status: unhealthy
Age Group: adolescents; adults
Sex: M+F
Sources:
Upper limb fracture 0.1%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
Health Status: unhealthy
Age Group: adolescents; adults
Sex: M+F
Sources:
Viral infection 0.1%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
Health Status: unhealthy
Age Group: adolescents; adults
Sex: M+F
Sources:
Depression 0.1%
Disc. AE
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
Health Status: unhealthy
Age Group: adolescents; adults
Sex: M+F
Sources:
Fall 0.1%
Disc. AE
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
Health Status: unhealthy
Age Group: adolescents; adults
Sex: M+F
Sources:
Hyperbilirubinemia 0.1%
Disc. AE
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
Health Status: unhealthy
Age Group: adolescents; adults
Sex: M+F
Sources:
Irritable bowel syndrome 0.1%
Disc. AE
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
Health Status: unhealthy
Age Group: adolescents; adults
Sex: M+F
Sources:
Joint injury 0.1%
Disc. AE
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
Health Status: unhealthy
Age Group: adolescents; adults
Sex: M+F
Sources:
Lactose intolerance 0.1%
Disc. AE
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
Health Status: unhealthy
Age Group: adolescents; adults
Sex: M+F
Sources:
Meniscus lesion 0.1%
Disc. AE
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
Health Status: unhealthy
Age Group: adolescents; adults
Sex: M+F
Sources:
Metamorphopsia 0.1%
Disc. AE
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
Health Status: unhealthy
Age Group: adolescents; adults
Sex: M+F
Sources:
Musculoskeletal pain 0.1%
Disc. AE
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
Health Status: unhealthy
Age Group: adolescents; adults
Sex: M+F
Sources:
Night blindness 0.1%
Disc. AE
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
Health Status: unhealthy
Age Group: adolescents; adults
Sex: M+F
Sources:
Pneumonia 0.1%
Disc. AE
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
Health Status: unhealthy
Age Group: adolescents; adults
Sex: M+F
Sources:
Rash 0.1%
Disc. AE
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
Health Status: unhealthy
Age Group: adolescents; adults
Sex: M+F
Sources:
Soft tissue injury 0.1%
Disc. AE
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
Health Status: unhealthy
Age Group: adolescents; adults
Sex: M+F
Sources:
Thermal burn 0.1%
Disc. AE
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
Health Status: unhealthy
Age Group: adolescents; adults
Sex: M+F
Sources:
Upper abdominal pain 0.1%
Disc. AE
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
Health Status: unhealthy
Age Group: adolescents; adults
Sex: M+F
Sources:
Upper limb fracture 0.1%
Disc. AE
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
Health Status: unhealthy
Age Group: adolescents; adults
Sex: M+F
Sources:
Viral infection 0.1%
Disc. AE
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
Health Status: unhealthy
Age Group: adolescents; adults
Sex: M+F
Sources:
GFR decreased 0.2%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
Health Status: unhealthy
Age Group: adolescents; adults
Sex: M+F
Sources:
GFR decreased 0.2%
Disc. AE
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
Health Status: unhealthy
Age Group: adolescents; adults
Sex: M+F
Sources:
Hemoglobin decreased 0.4%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
Health Status: unhealthy
Age Group: adolescents; adults
Sex: M+F
Sources:
Hemoglobin decreased 0.4%
Disc. AE
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
Health Status: unhealthy
Age Group: adolescents; adults
Sex: M+F
Sources:
Malaria 0.5%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
Health Status: unhealthy
Age Group: adolescents; adults
Sex: M+F
Sources:
Malaria 0.5%
Disc. AE
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
Health Status: unhealthy
Age Group: adolescents; adults
Sex: M+F
Sources:
ALT increased 0.7%
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
Health Status: unhealthy
Age Group: adolescents; adults
Sex: M+F
Sources:
ALT increased 0.7%
Disc. AE
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy, adolescents; adults
Health Status: unhealthy
Age Group: adolescents; adults
Sex: M+F
Sources:
Nausea 1 patient
Disc. AE
400 mg 1 times / day multiple, oral
Studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources:
healthy
Vomiting 1 patient
Disc. AE
400 mg 1 times / day multiple, oral
Studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources:
healthy
Hemoglobin increased 2%
600 mg single, oral
Studied dose
healthy
Hypersensitivity 2%
600 mg single, oral
Studied dose
healthy
CPK increased 4%
600 mg single, oral
Studied dose
healthy
Overview

Overview

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no [IC50 18 uM]
no [IC50 54 uM]
no [IC50 7.1 uM]
no [IC50 81 uM]
no [IC50 >25 uM]
no [IC50 >25 uM]
no [IC50 >25 uM]
no [IC50 >25 uM]
yes [IC50 0.282 uM]
yes [IC50 0.632 uM]
yes [IC50 1.99 uM]
yes [IC50 15 uM]
yes [IC50 5.61 uM]
yes [Ki 15 uM]
no (co-administration study)
Comment: Subsequent clinical DDI studies demonstrated no clinically significant effects of TQ on the PK of desipramine (CYP2D6 substrate) (Study SB252263/015), caffeine (CYP1A2 substrate), midazolam (CYP3A4 substrate), and flurbiprofen (CYP2C9 substrate) (Study SB252263/040).
Page: 72
yes [Ki 5.2 uM]
no (co-administration study)
Comment: Subsequent clinical DDI studies demonstrated no clinically significant effects of TQ on the PK of desipramine (CYP2D6 substrate) (Study SB252263/015), caffeine (CYP1A2 substrate), midazolam (CYP3A4 substrate), and flurbiprofen (CYP2C9 substrate) (Study SB252263/040).
Page: 72
yes
yes
no (co-administration study)
Comment: Subsequent clinical DDI studies demonstrated no clinically significant effects of TQ on the PK of desipramine (CYP2D6 substrate) (Study SB252263/015), caffeine (CYP1A2 substrate), midazolam (CYP3A4 substrate), and flurbiprofen (CYP2C9 substrate) (Study SB252263/040).
Page: 72
yes
no (co-administration study)
Comment: Subsequent clinical DDI studies demonstrated no clinically significant effects of TQ on the PK of desipramine (CYP2D6 substrate) (Study SB252263/015), caffeine (CYP1A2 substrate), midazolam (CYP3A4 substrate), and flurbiprofen (CYP2C9 substrate) (Study SB252263/040).
Page: 72
Drug as victimTox targets

Tox targets

PubMed

PubMed

TitleDatePubMed
Isolation and characterization of rat lung Pneumocystis carinii gp120.
1991 Nov-Dec
8-aminoquinolines effective against Pneumocystis carinii in vitro and in vivo.
1993 Oct
Experiences with malaria chemoprophylaxis in Dutch troops.
2001
Malaria prophylaxis/radical cure: recent experiences of the Australian Defence Force.
2001
[Plasmodium vivax: therapy update].
2001 Apr 21
Development of new drugs for chemoprophylaxis of malaria.
2001 Jul
Triangular test applied to the clinical trial of azithromycin against relapses in Plasmodium vivax infections.
2002 Nov 12
Blood schizontocidal activity of WR 238605 (Tafenoquine) against Plasmodium cynomolgi and Plasmodium fragile infections in rhesus monkeys.
2003 Apr
Military aviators, special operations forces, and causal malaria prophylaxis.
2003 Dec
Efficacy of monthly tafenoquine for prophylaxis of Plasmodium vivax and multidrug-resistant P. falciparum malaria.
2004 Oct 15
New strategies for the prevention of malaria in travelers.
2005 Mar
A plant-derived morphinan as a novel lead compound active against malaria liver stages.
2006 Dec
Intermittent preventive treatment for malaria in pregnancy in Africa: what's new, what's needed?
2007 Feb 16
Selective plasma protein binding of antimalarial drugs to alpha1-acid glycoprotein.
2008 Apr 1
Prevalence of contraindications to mefloquine use among USA military personnel deployed to Central Asia.
2008 Feb 11
Glucose-6-phosphate dehydrogenase deficiency in an endemic area for malaria in Manaus: a cross-sectional survey in the Brazilian Amazon.
2009
Plasmodium berghei ANKA: selection of resistance to piperaquine and lumefantrine in a mouse model.
2009 Jul
Visualisation and quantitative analysis of the rodent malaria liver stage by real time imaging.
2009 Nov 18
Gateways to clinical trials.
2010 Jun
In vitro selection of Plasmodium falciparum drug-resistant parasite lines.
2010 Mar
Operational strategies to achieve and maintain malaria elimination.
2010 Nov 6
Patents

Patents

Sample Use Guides

Loading regimen: 200 mg (2 of the 100 mg tablets) once daily for 3 days
Route of Administration: Oral
After 72 h of tafenoquine exposure, proliferation of L. donovani and Leishmania major promastigotes was inhibited at the micromolar range in a dose-dependent manner, with 50% effective concentrations (EC50s) of 5.6 ± 1.0 uM and 5.3 ± 2.1 uM for L. donovani.
Substance Class Chemical
Created
by admin
on Sat Jun 26 09:09:16 UTC 2021
Edited
by admin
on Sat Jun 26 09:09:16 UTC 2021
Record UNII
262P8GS9L9
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TAFENOQUINE
INN   MART.   MI   USAN   WHO-DD  
INN   USAN  
Official Name English
TAFENOQUINE [MI]
Common Name English
SB-252263-AAB
Code English
TAFENOQUINE [WHO-DD]
Common Name English
TAFENOQUINE [INN]
Common Name English
TAFENOQUINE [MART.]
Common Name English
TAFENOQUINE [USAN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C271
Created by admin on Sat Jun 26 09:09:16 UTC 2021 , Edited by admin on Sat Jun 26 09:09:16 UTC 2021
FDA ORPHAN DRUG 385812
Created by admin on Sat Jun 26 09:09:16 UTC 2021 , Edited by admin on Sat Jun 26 09:09:16 UTC 2021
Code System Code Type Description
MERCK INDEX
M10429
Created by admin on Sat Jun 26 09:09:16 UTC 2021 , Edited by admin on Sat Jun 26 09:09:16 UTC 2021
PRIMARY Merck Index
CAS
106635-80-7
Created by admin on Sat Jun 26 09:09:16 UTC 2021 , Edited by admin on Sat Jun 26 09:09:16 UTC 2021
PRIMARY
EVMPD
SUB04666MIG
Created by admin on Sat Jun 26 09:09:16 UTC 2021 , Edited by admin on Sat Jun 26 09:09:16 UTC 2021
PRIMARY
NCI_THESAURUS
C73006
Created by admin on Sat Jun 26 09:09:16 UTC 2021 , Edited by admin on Sat Jun 26 09:09:16 UTC 2021
PRIMARY
PUBCHEM
115358
Created by admin on Sat Jun 26 09:09:16 UTC 2021 , Edited by admin on Sat Jun 26 09:09:16 UTC 2021
PRIMARY
MESH
C055852
Created by admin on Sat Jun 26 09:09:16 UTC 2021 , Edited by admin on Sat Jun 26 09:09:16 UTC 2021
PRIMARY
FDA UNII
262P8GS9L9
Created by admin on Sat Jun 26 09:09:16 UTC 2021 , Edited by admin on Sat Jun 26 09:09:16 UTC 2021
PRIMARY
DRUG BANK
DB06608
Created by admin on Sat Jun 26 09:09:16 UTC 2021 , Edited by admin on Sat Jun 26 09:09:16 UTC 2021
PRIMARY
RXCUI
2054023
Created by admin on Sat Jun 26 09:09:16 UTC 2021 , Edited by admin on Sat Jun 26 09:09:16 UTC 2021
PRIMARY
LACTMED
Tafenoquine
Created by admin on Sat Jun 26 09:09:16 UTC 2021 , Edited by admin on Sat Jun 26 09:09:16 UTC 2021
PRIMARY
DRUG CENTRAL
3578
Created by admin on Sat Jun 26 09:09:16 UTC 2021 , Edited by admin on Sat Jun 26 09:09:16 UTC 2021
PRIMARY
ChEMBL
CHEMBL298470
Created by admin on Sat Jun 26 09:09:16 UTC 2021 , Edited by admin on Sat Jun 26 09:09:16 UTC 2021
PRIMARY
INN
7835
Created by admin on Sat Jun 26 09:09:16 UTC 2021 , Edited by admin on Sat Jun 26 09:09:16 UTC 2021
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> INHIBITOR
Ki
METABOLIC ENZYME -> SUBSTRATE
TRANSPORTER -> INHIBITOR
IC50
TARGET -> INHIBITOR
IC50
METABOLIC ENZYME -> INHIBITOR
Ki
METABOLIC ENZYME -> INHIBITOR
Ki
TRANSPORTER -> INHIBITOR
IC50
METABOLIC ENZYME -> INHIBITOR
Ki
METABOLIC ENZYME -> INHIBITOR
Ki
SALT/SOLVATE -> PARENT
BINDER->LIGAND
BINDING
TRANSPORTER -> INHIBITOR
IC50
TARGET ORGANISM->INHIBITOR
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Tmax PHARMACOKINETIC POST-DOSE

Biological Half-life PHARMACOKINETIC